TargetMol

LB-80380 maleate salt

Product Code:
 
TAR-T32611
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T32611-5mg5mg£1,091.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T32611-50mg50mg£2,143.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T32611-100mg100mg£2,801.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
LB-80380 maleate salt, a novel phosphonate nucleoside, is for the potential treatment of HBV infection.
CAS:
1039623-01-2
Formula:
C26H38N5O11P
Molecular Weight:
627.588
Purity:
0.98
SMILES:
OC(=O)C=C/C(O)=O.CC(C)(C)C(=O)OCOP(COC1(Cn2cnc3cnc(N)nc23)CC1)OCOC(=O)C(C)(C)C

References

1. Papatheodoridis GV, Manolakopoulos S. Drug evaluation: LB-80380--a novel phosphonate nucleoside for the potential treatment of HBV infection. Curr Opin Mol Ther. 2006 Aug;8(4):352-7. Review. PubMed PMID: 16955699. 2. Lampertico P. Oral antiviral therapy for hepatitis B: the case of besifovir, a new kid on the block with a long way to go. Gut. 2014 Jun;63(6):869-70. doi: 10.1136/gutjnl-2013-305859. Epub 2013 Oct 25. PubMed PMID: 24162592. 3. Yuen MF, Ahn SH, Lee KS, Um SH, Cho M, Yoon SK, Lee JW, Park NH, Kweon YO, Sohn JH, Lee J, Kim JA, Lai CL, Han KH. Two-year treatment outcome of chronic hepatitis B infection treated with besifovir vs. entecavir: results from a multicentre study. J Hepatol. 2015 Mar;62(3):526-32. doi: 10.1016/j.jhep.2014.10.026. Epub 2014 Oct 25. PubMed PMID: 25450709. 4. Lai CL, Ahn SH, Lee KS, Um SH, Cho M, Yoon SK, Lee JW, Park NH, Kweon YO, Sohn JH, Lee J, Kim JA, Han KH, Yuen MF. Phase IIb multicentred randomised trial of besifovir (LB80380) versus entecavir in Asian patients with chronic hepatitis B. Gut. 2014 Jun;63(6):996-1004. doi: 10.1136/gutjnl-2013-305138. Epub 2013 Aug 26. PubMed PMID: 23979965.